CA-ADAP Formulary Review: AGENDA

1. Disease State Overview
2. Medications
3. Denied claims data
4. Other ADAP formularies
5. Recommendations
6. Discussion
Therapeutic Class Review

LONG-ACTING INJECTABLE ANTIPSYCHOTIC AGENTS
Features of Schizophrenia

• **Schizophrenia**: A chronic brain disorder where people interpret reality abnormally. It affects how a person thinks, feels, and behaves.
  
  − Positive symptoms:
    
    • Hallucinations
    • Delusions
    • Paranoia
    • Exaggerated or distorted perceptions, beliefs, and behaviors
  
  − Negative symptoms:
    
    • Flattened affect
    • Reduced ability to experience pleasure
    • Decreased desire to initiate plans
  
  − Disorganized symptoms:
    
    • Confused and disordered thinking and speech
    • Bizarre behavior
    • Abnormal movements
    • Trouble with logical thinking
  
  − Cognition can also be affected, leading to problems with attention, concentration and memory, and to declining educational performance
Schizophrenia and Co-Morbid Conditions

• Other conditions, including HIV infection, are more frequent in people with serious mental illness

• Mortality is increased in individuals with schizophrenia, and the average life span is shortened by a decade or more (typically related to comorbid conditions)

• Mental health is a strong predictor of adherence to meds
  - Managing mental health can improve quality of life and psychological well-being, therefore increasing adherence to ARV therapy
Treatment of Schizophrenia

• Schizophrenia requires lifelong treatment, even when symptoms have subsided
  o **Goals of Treatment**: symptom remission and restoring baseline function at the lowest possible dose

• General guidelines, particularly for patients with symptomatic HIV disease, include the following:
  o Using lower starting doses and slower titration
  o Providing the least complicated dosing schedules possible
  o Focusing on drug side effect profiles to avoid unnecessary adverse events
  o Maintaining awareness of drug metabolism/clearance pathways to minimize drug-drug interactions and possible end organ damage.

• Clinical guidelines suggest treatment with a single agent but do not recommend any agent over another
  o Treatment with more than one antipsychotic should be avoided
Long-Acting Injectables (LAIs)

• The American Psychiatric Association (APA) guidelines suggests LAI if:
  o Patient preference
  o Non-Adherence history

• LAIs may be preferred for:
  o Difficulty swallowing pills
  o Ambivalence
  o Inconsistent in swallowing
  o Difficulty remembering

• LAIs may be warranted when:
  o Not responding to oral agent
  o Transitioning between settings
  o Early in schizophrenia treatment
  o Known substance abuse disorder
Long-Acting Injectables (LAI{s}) cont’d

• **Benefits:**
  - Decreased risk of mortality
  - Reduced risk of hospitalization
  - Decreased rates of discontinuation
  - ADRs may be less problematic
  - Sense of better control
  - Better adherence
  - Greater convenience

• **Harms:**
  - ADRs may last longer
  - Injection-related ADRs
  - Longer time to steady-state
Long-Acting Injectable – 1st Generation

- **Mechanism of Action:** Dopamine receptor antagonists
- **Place in Therapy:** **Not** recommended as initial therapy for most patients
- **Side effects:** High incidence of EPS, sedation, cardiac abnormalities, hyperprolactinemia, neuroleptic malignant syndrome (NMS)

<table>
<thead>
<tr>
<th>AGENT</th>
<th>GENERIC</th>
<th>CT</th>
<th>TX</th>
<th>WA</th>
<th>STRENGTHS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluphenazine</td>
<td>Y</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>•2.5mg, 5mg, 25mg</td>
</tr>
<tr>
<td>(PROLIXIN)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haloperidol</td>
<td>Y</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>•50mg, 100mg</td>
</tr>
<tr>
<td>(HALDOL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Long-Acting Injectable – 2\textsuperscript{nd} Generation

- Mechanism of Action: Serotonin-dopamine antagonists
- Place in Therapy: Recommended as \textit{initial therapy} for most patients
- Side effects: weight gain and related metabolic effects, hypotension, sedation, anticholinergic symptoms, hyperprolactinemia, EPS, cardiac effects, and sexual dysfunction

<table>
<thead>
<tr>
<th>AGENT</th>
<th>GENERIC</th>
<th>CT</th>
<th>TX</th>
<th>WA</th>
<th>STRENGTHS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aripiprazole (ABILIFY MAINTENA)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>•300mg, 400mg</td>
</tr>
<tr>
<td>Aripiprazole lauroxil (ARISTADA)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>•441mg, 662mg, 882mg, 1064mg, 675mg (Initio)</td>
</tr>
<tr>
<td>Olanzapine pamoate (ZYPREXA RELPREVV)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>•210mg, 300mg, 405mg</td>
</tr>
<tr>
<td>Paliperidone (INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>•39mg, 78mg, 117mg, 156mg, 234mg, 273mg, 410mg, 546mg, 819mg</td>
</tr>
<tr>
<td>Risperidone (RISPERDAL CONSTA)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>•12.5mg, 25mg, 37.5mg, 50mg</td>
</tr>
</tbody>
</table>
### Long-Acting Injectable Rejected Claims

<table>
<thead>
<tr>
<th>AGENT</th>
<th>REJECTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olanzapine pamoate (ZYPREXA RELPREVV)</td>
<td>-</td>
</tr>
<tr>
<td>Risperidone (RISPERDAL CONSTA)</td>
<td>1.5%</td>
</tr>
<tr>
<td>Fluphenazine (PROLIXIN)</td>
<td>3%</td>
</tr>
<tr>
<td>Haloperidol (HALDOL)</td>
<td>8.5%</td>
</tr>
<tr>
<td>Aripiprazole (ABILIFY MAINTENA)</td>
<td>18%</td>
</tr>
<tr>
<td>Aripiprazole lauroxil (ARISTADA)</td>
<td>20%</td>
</tr>
<tr>
<td>Paliperidone (INVEGA SUSTENNA, INVEGA TRINZA)</td>
<td>49%</td>
</tr>
</tbody>
</table>
Formulary Management
Recommendations: Schizophrenia

- **Paliperidone (INVEGA)**: Recommend addition to the ADAP formulary
- **Aripiprazole (ABILIFY MAINTENA)**: Consider addition to the ADAP formulary
- **Aripiprazole Lauroxil (ARISTADA)**: Consider addition to the ADAP formulary
References


Confidentiality statement

By receipt of this presentation, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, or distributed to or disclosed to others at any time without the prior written consent of Magellan Health, Inc.

The information contained in this presentation is intended for educational purposes only and is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment.

The information contained in this presentation is intended for educational purposes only and should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.